



III International Conference on

Vaccines R&D-2017

# VACCINES RESEARCH & DEVELOPMENT

November 13-15, 2017 | Washington, D.C., USA

## PROGRAM

### Conference Topics

Cancer Vaccines  
Veterinary Vaccines  
Infectious & Non-Infectious Diseases  
Biodenense Vaccines  
Vaccines Against Respiratory Pathogens  
Influenza Vaccines/Virus  
Passive Vaccines  
New Vaccine Development  
Therapeutic Vaccination  
Clinical Trials  
DNA Vaccines  
Technologies, Bioprocessing & Manufacturing

### Conference Highlights

Keynote Speakers Session  
Symposium on HIV vaccines  
Multiple track sessions  
Participation from pharma, vaccines, biotech small to medium cap companies  
Networking & Partnering opportunities  
Key issues in Q&A panel sessions  
Excellent line-up of renowned speakers from govt, academia, industry and non-profit organizations  
Poster presentations

Organizer



Bronze Sponsor



Exhibitor



Supporting Sponsor



Venue

**Sheraton Reston Hotel**

11810 Sunrise Valley Dr, Reston

VA 20191

USA

Ph: +1 703-620-9000

**Day-1 November 13, 2017**

08:00-08:30 **Registrations**

08:30-09:00 **Conference Inauguration Ceremony**

**Keynote Speakers**

09:00-09:30 **Title:** *Translation of cancer vaccines from mice to human clinical trials*  
**Jay A. Berzofsky**, National Cancer Institute, USA

09:30-10:00 **Title:**  
**Nancy Sullivan**, Vaccine Research Center NIH/NIAID, USA

10:00-10:30 **Title:** *Vaccine design to safely induce protective immunity of long duration*  
**Roy Curtiss III**, University of Florida, USA

10:30-11:00 **Title:**  
**Peter L. Nara**, Biological Mimetics, Inc., USA

**Coffee Break & Networking 11:00-11:30**

11:30-12:00 **Title:**  
**Manuel Elkin Patarroyo M**, FIDIC, Colombia

12:00-12:30 **Title:**  
**Stephen L. Hoffman**, Sanaria Inc., USA

12:30-13:00 **Title:** *A key to the backdoor into the castle: The clinical ramifications of immunoediting driven by antigenic competition*  
**Michael G. Hanna**, Vaccinogen, Inc., USA

**Lunch & Networking 13:00-14:00**

14:00-14:30 **Title:**  
**Odile Leroy**, European Vaccine Initiative, Germany

14:30-15:00 **Title:**  
**David B. Weiner**, The Wistar Institute Vaccine Center, USA

15:00-15:30 **Special Talk**  
**Title:** *Development of vaccines using Sendai virus vectors*  
**Tetsuro Matano**, National Institute of Infectious Diseases, Japan

**Coffee Break & Networking 15:30-16:00**

**"Special Session on Vaccine Regulation"**

16:00-16:30 **Title:** *Challenges for registration of vaccines at global level*  
**Nora Dellepiane**, Serum Institute of India Pvt. Ltd

16:30-17:00  
**Title:** *Regulatory considerations for preventive vaccine development: A U.S. FDA perspective*  
**Kelsy Hoffman**, CBER/FDA

17:00-17:30 **Title:**  
**Bartholomew Dicky Akanmori**, WHO/Afro

17:30-18:00 **Title:** *Vaccine research and development in china: Status of product development and regulatory land scope*

**Li Shi**, Shanghai Zerun Biotechnology Co.,Ltd, China

18:00-18:30

**Title:** *Routine immunization in developing countries: Civil war and religious misconception briefs*

**Hermengild Mayunga**, Tanzania Parliamentary Against Malaria & Neglected Tropical Diseases, Tanzania

18:30-19:30

**Networking & Drink reception**

18:30-19:00

**Poster Presentations**

**Title:** *A Phase I trial of immunotherapy with INO-5150 for treatment of biochemically relapsed prostate cancer*

**Li Liu**, Inovio Pharmaceuticals, USA

**Title:** *Elimination of immunodominant B cells drives the germinal center reaction toward subdominant epitopes: A potential vaccination strategy to target broadly neutralizing epitopes*

**Murillo Silva**, Northeastern University, USA

**Title:** *Overcoming bioprocess research and development hurdles to advance an LVV candidate for human cytomegalovirus*

**Matthew Woodling**, Merck & Co., Inc., USA

**Title:** *Toward developing antibody-drugs for prophylaxis of HTLV-I infection and onset of Adult T-cell Leukemia (ATL)*

**Yuetsu TANAKA**, University of the Ryukyus, USA

**Title:** *Optimization of Fc receptor targeting for improved mucosal vaccine delivery*

**Sudeep Kumar**, Albany Medical College, USA

**Title:** *Enhanced protection induced by virus-like particle vaccine containing tandem repeat gene of respiratory syncytial virus G protein*

**Fu Shi Quan**, Kyung Hee University School of Medicine, Korea

**Title:** *Process development of a glycoconjugate vaccine*

**Tracy Scott**, Pfizer, Inc., USA

**Title:** *Yeast cell surface display of HIV envelope proteins for vaccine development*

**Hong Zhu**, University of Rochester, USA

**Title:** *Immunoglobulin response to the low polymorphic Pf113 antigen in children from Lastoursville, South-East of Gabon*

**Jean Bernard LEKANA-DOUKI**, Centre International de Recherches Médicales de Franceville, Gabon

**Title:** *Expression of edema factor gene in plants-a novel step in the generation of edible vaccine against anthrax*

**Prerna Chaudhary**, Jawaharlal Nehru University, India

**Title:** *Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A*

**Anne Wajja**, MRC/UVRI Uganda Research Unit on AIDS

**Title:** *Pregnant women's willingness and factors that influence the decisions to consent to their child's participation in HIV vaccine clinical trials in an urban setting in Mozambique*

**Afonso Mazine Tiago Fumo**, Catholic University of Mozambique, Mozambique

**Day-2 November 14, 2017**

**Track-A**

**Symposium Title: The long road to an HIV vaccine**

08:00-10:30 **Co-chairs :** Richard Wyatt & Susan Zolla-Pazner

**Keynote Speakers**

08:00-08:30

**Title:** *Targeting selected epitopes in the development of an effective prophylactic HIV vaccine*

**Susan Zolla-Pazner**, Icahn School of Medicine at Mount Sinai

08:30-09:00 **Title:**

**Hanneke Schuitemaker**, Janssen Vaccines, The Netherlands

09:00-09:30 **Title:**

**Louis Picker**, Oregon Health & Science University, USA

09:30-10:00 **Title:** *Obstacles to and prospects for an effective HIV-1 vaccine*

**Neil S. Greenspan**, Case Western Reserve University, USA

10:00-10:30 **Title:** *Developing a preventive HIV vaccine requires solving inverse problems which is not feasible by rational vaccine design*

**Marc Van Regenmortel**, Strasbourg University, France

**Coffee Break & Networking 10:30-11:00**

11:00-13:05 **Session-I Co-chairs :** Marjorie Robert-Guroff & Neil S. Greenspan

11:00-11:25 **Title:** *HIV Env trimer immunogen design and modification to elicit neutralizing antibodies*

**Richard Wyatt**, Scripps Institute in La Jolla, CA USA

11:25-11:50 **Title:** *HIV/AIDS vaccine development: Defending the frontline*

**Ruth Ruprecht**, Texas Biomedical Research Institute, USA

11:50-12:15 **Title:** *Fundamental challenges to the development of an HIV vaccine*

**Adan Rios**, University of Texas Medical School in Houston, USA

12:15-12:40 **Title:** *Host genetic variability and HIV vaccines: a focus on low affinity Fcγ receptors*

**Caroline T Tiemessen**, National Institute for Communicable Diseases South Africa

12:40-13:05 **Title:** *Orally delivered mucosal vaccine targeting colorectal immunity protected SHIV transmission in macaques*  
**Yongjun Sui**, National Cancer Institute, USA

**Lunch & Networking 13:05-14:05**

14:05-15:45 **Session-II Co-chairs :** Ruth Ruprecht & Jose Esparza

14:05-14:30 **Title:**  
**Angus Dalgleish**, St George's, University of London

14:30-14:55 **Title:** *HIV vaccines: How we got where we are today and where we want to be in 2030?*  
**Jose Esparza**, University of Maryland School of Medicine, USA

14:55-15:20 **Title:** *A sex bias in SIV vaccine protective efficacy: implications for HIV vaccine development*  
**Marjorie Robert-Guroff**, National Cancer Institute, USA

15:20-15:45 **Title:** *A HIV vaccine based on MTVV prime Adv boost controlled viral reservoir and conferred long-term protection from SIVmac239 infection*  
**Ling Chen**, Guangzhou Medical University, China

**Coffee Break & Networking 15:45-16:10**

16:10-18:15 **Session-III Co-chairs :** Hanneke Schuitemaker & Marc Van Regenmortel

16:10-16:35 **Title:** *The road to a pediatric HIV vaccine*  
**Kristina De Paris**, UNC at Chapel Hill, USA

16:35-17:00 **Title:** *HIV Env antibody can provide sterilizing immunity in the strictest sense*  
**Klaus Überla**, University Hospital Erlangen, Virology Institute, Germany

17:00-17:25 **Title:** *Mucosal vaccination with accessory antigens provides surprisingly robust protection against early SIV replication. Underappreciated role of location and immunodominance in vaccination against chronic infection?*  
**Peter Johannes Holst**, University of Copenhagen, Denmark

17:25-17:50 **Title:** *Stabilization of gp120 outer domain for HIV vaccine immunogen design*  
**Shi-hua Xiang**, University of Nebraska-Lincoln, Nebraska Center for Virology, USA

17:50-18:15 **Title:** *Identification of HIV-1 gp41 Residues that Modulate Envelope CD4 Reactivity*  
**Paul W. Keller**, US Food and Drug Administration, USA

**Day-3 Nov 15, 2017**

**Track-A (continues)**

**Session-IV Co-chairs:** Catarina E. Hioe & Caroline T Tiemessen

08:00-08:25 **Title:** *Improving antibody response to targeted epitopes of HIV envelope by immune complex vaccines*  
**Catarina E. Hioe**, Mount Sinai School of Medicine, USA

08:25-08:50 **Title:** *Control of heterologous SIVmac251 in macaques immunized with an HIV lentivector prototype*  
**Yahia Chebloune**, University Grenoble Alpes, France

08:50-09:15 **Title:** *Critical review of Therapeutic Vaccines for the functional cure of the HIV Infection: lessons learned within clinical development programs, 2011-2017*  
**Shahin Gharakhanian**, Shahin Gharakhanian MD Consulting LLC, USA

09:15-09:40 **Title:** *Efficacy of novel epithelial stem cell-based AIDS vaccine to induce mucosal immune responses and protect against SIV challenge in macaques*  
**Marie-Claire Gauduin**, Texas Biomedical Research Institute, USA

09:40-10:05 **Title:** *Immunogen design to target HIV-1 envelope glycoprotein gp41*  
**Bing Chen**, Boston Children's Hospital, USA

**Coffee Break 10:05-10:30**

10:30-10:55 **Title:** *New Technologies to evaluate vaccine-induced immune responses*  
**Spyros A. Kalams**, Vanderbilt University Medical Center, USA

10:55-11:20 **Title:** *Safety and Immune Responses of Additional Boosting of the previous ALVAC<sup>®</sup>-HIV/AIDS VAX<sup>®</sup> B/E vaccines priming and boosting regimen (RV144)*  
**Punnee Pitisuttithum**, Mahidol University, Thailand

**Day-2 November 14, 2017**

**Track-B**

**Cancer Vaccines**

**Session Chair: Michael G. Hanna**, Vaccinogen, Inc., USA

08:00-08:25 **Title:** *Targeting tumor associated carbohydrate antigens for cancer therapy*  
**Thomas Kieber-Emmons**, University of Arkansas for Medical Sciences, USA

08:25-08:50 **Title:** *Nano-vaccine platform technology for personalized cancer vaccination*  
**James J. Moon**, University of Michigan, USA

08:50-09:15 **Title:** *Tumor liberated protein (TLP) as potential vaccine for lung cancer patients*  
**Giulio Tarro**, Fondazione de Beaumont Bonelli per le ricerche sul cancro, Italy

09:15-09:40 **Title:** *Combining local immunotoxins targeting mesothelin with CTLA-4 blockade synergistically eradicates murine cancer by promoting anti-cancer immunity*  
**Jasmin Leshem**, National Cancer Institute, USA

09:40-10:05  
**Title:** *Analyses of data on pathogen-specific vaccines: Weakening or Promoting Immunity?*  
**Mahin Khatami**, National Cancer Institute (retired), USA

**Coffee Break & Networking 10:05-10:30**

10:30-10:55 **Title:** *Synthetic immunogens drive potent antigen specific anti-tumor immune responses*  
**Bernadette Ferraro**, Inovio Pharmaceuticals, USA

10:55-11:20 **Title:** *Curative efficacy of therapeutic mucosal HPV E6/E7 peptide vaccination combined with checkpoint modulation in preclinical mouse models of HPV+ genital and oral cancer*  
**Jagannadha Sastry**, MD Anderson Cancer Center, USA

11:20-11:45 **Title:** *Enhancing the therapeutic efficacy of mucosal HPV E6/E7 peptide vaccination with checkpoint modulation in preclinical mouse models of HPV+ oral cancers*  
**Stephanie Dorta-Estremera**, MD Anderson Cancer Center, USA

11:45-12:10 **Title:** *Changing the tumor microenvironment of PDAC by novel immune-chemotherapeutic approaches*  
**Benson C. Selvanesan**, Albert Einstein College of Medicine

12:10-12:35 **Title:** *Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteins*  
**Nicolas Çuburu**, National Cancer Institute, USA

12:35-13:00 **Title:** *Cell immunogene therapy of cancers using anti - gene anti IGF-I vaccines*  
**Jerzy Trojan**, UNAB University, Colombia

**Lunch & Networking 13:00-14:00**

14:00-14:25 **Title:** *Great Apes Adenovirus neoantigens-based vaccine synergizes with immunomodulators in mouse models of cancer*  
**Anna Morena D'Alise**, Nouscom AG, Switzerland

14:25-14:50 **Title:** *Lysosomal-associated membrane protein-1-targeting of antigen for increased efficacy of DNA vaccination*  
**Pratima Sinha**, Immunomic Therapeutics Inc., USA

14:50-15:15 **Title:** *A new source of neoantigens offers new approaches to personal and preventative cancer vaccines*  
**Stephen Albert Johnston**, Arizona State University, USA

15:15-15:40 **Title:** *A rapid platform / assay for immunogenicity testing of cancer (neo)epitopes amenable to predict responders from non-responders*  
**Pirouz Daftarian**, MBL International, USA

**Veterinary Vaccines**

**Session Chair:**

15:40-16:05 **Title:** *Veterinary vaccine research in support of biodefense and the threat of biological threat agents*  
**Cyril Gerard Gay**, USDA/ARS, USA

**Coffee Break & Networking 16:05-16:30**

16:30-16:55 **Title:** *Characterization and cross-protection evaluation of M949\_1603 gene deletion Riemerella anatipestifer mutant RA-M1*  
**Shengqing YU**, Shanghai Veterinary Research Institute, China

16:55-17:20 **Title:** *Immune responses to Mycobacterium bovis in naturally infected ruminants*  
**Gordon Harkiss**, MV Diagnostics Ltd, UK

17:20-17:45 **Title:** *Efficacy of live attenuated vaccine to prevent abortion due to Neospora caninum in ruminants*  
**Sophie Barreteau**, VitamFero S.A., France

- 17:45-18:10 **Title:** *Novel universal nanoparticle vaccines for bird flu and coronavirus infections in birds*  
**Jianping Li**, University of Connecticut, USA
- 18:10-18:35 **Title:** *Recombinant porcine reproductive and respiratory syndrome virus strain P129 expressing CSFV E2 glycoprotein enhanced pathogenesis of CSFV in pigs*  
**Lihua Wang**, Kansas State University, USA
- 18:35-19:00 **Title:** *Development of a one-dose classical swine fever sub-unit vaccine*  
**Rachel Madera**, Kansas State University, USA
- 19:00-19:25 **Title:** *Combination adjuvants in subunit veterinary vaccines*  
**Yulia Burakova**, Kansas State University, USA

**Networking**

**Day-2 November 14, 2017**

**Track-C**

**Infectious & Non-Infectious Diseases**

**Session Chair: Marcelo B. Sztein**, University of Maryland, USA

- 08:00-08:25 **Title:** *Turning a corner? progress in Tuberculosis (TB) vaccine development*  
**Ann M. Ginsberg**, Aeras, USA

- 08:25-08:50 **Title:** *Correlates of protection from S. Typhi infection in humans: Recent advances*  
**Marcelo B. Sztein**, University of Maryland, USA

- 08:50-09:15 **Title:** *Live attenuated chimerivax-zika vaccine candidate*  
**Konstantin Pugachev**, Sanofi Pasteur, USA

- 09:15-09:40 **Title:** *T cell-mediated immune responses induced by the oral live-attenuated Shigella vaccine candidate CVD 1208S in humans*  
**Franklin R. Toapanta**, University of Maryland, USA

09:40-10:05

**Title:** *Initial and long-term stability study of Pfs230-EPA conjugates adjuvanted with Alhydrogel®*  
**Daming Zhu**, National Institute of Health, USA

**Coffee Break & Networking 10:05-10:30**

- 10:30-10:55 **Title:** *Herpes Simplex Virus (HSV) gD-2 Vaccine Elicits High Titer FcR Activating Antibodies and Prevents Primary Infection and Latency in Multiple Small Animal Models*  
**Betsy Herold**, Albert Einstein College of Medicine, USA

- 10:55-11:20 **Title:** *A broad-spectrum anti-endotoxin vaccine for the prevention and treatment of Gram-negative bacterial infections*  
**Alan S Cross**, University of Maryland School of Medicine, USA

- 11:20-11:45 **Title:** *Development of novel and safe single-dose vaccines; preclinical efficacy data for zika, ebola and lassa fever*  
**Farshad Guirakhoo**, GeoVax Labs, USA

- 11:45-12:10 **Title:** *Immune frailty: role of viral infection and impact on vaccination in the elderly*



**Graham Pawelec**, University of Tuebingen, Germany

12:10-12:35 **Title:** *Novel epitopes identified from Mycobacterium tuberculosis antigen Rv2629 could induce cytotoxic T lymphocyte response*

**Bai Xuejuan**, the 309th Hospital of Chinese PLA, China

12:35-13:00

**Title:** *Seroprevalence of measles among children aged 5-10 years in Chandigarh, North India*

**Madhu Gupta**, Post Graduate Institute of Medical Education and Research, India

**Lunch & Networking 13:00-14:00**

14:00-14:25 **Title:** *Recombinant BCG expressing SOCS1 antagonist as a novel BCG vaccine*

**Yasuhiro Yasutomi**, National Institutes of Biomedical Innovation, Japan

**Biodefense Vaccines**

**Session Chair: Lallan Giri**, Biologics Resources LLC, USA

14:25-14:50 **Title:** *Deconvolution of neutralizing antibody response induced by a trivalent parainfluenza-vectored ebolavirus vaccine*

**J. Brian Kimble**, University of Texas Medical Branch, USA

14:50-15:15 **Title:** *Comparative analysis of the antibody threshold of protection for the licensed biothrax anthrax vaccine and other novel anthrax vaccine candidates*

**Mario H. Skiadopoulos**, Emergent BioSolutions Inc., USA

15:15-15:40 **Title:** *Conjugate rPA-PGA anthrax vaccine induces protective antibodies*

**Christine E. Ferragine**, Biologics Resources LLC, USA

15:40-16:05 **Title:** *Development of the VesiculoVax™ vaccine platform to rapidly respond to new epidemic diseases*

**Jennifer A. Schwartz**, Profectus BioSciences, Inc., USA

**Coffee Break & Networking 16:05-16:30**

16:30-16:55

**Title:** *Use of an outbred mouse model for Francisella tularensis vaccine development and testing*

**Raju Sunagar**, Albany Medical College, USA

16:55-17:20 **Title:** *Vaccine elicited broadly neutralizing antibodies against New World hemorrhagic fever arenaviruses*

**Jonathan Abraham**, Harvard Medical School, USA

**Networking**

**Day-3 November 15, 2017**

**Track-D**

**Influenza Vaccines/Virus**

**Session Chair: Jay Bream**, Johns Hopkins Bloomberg School of Public Health, USA

08:00-08:25 **Title:** *ADCC reporter bioassay and vaccine development*

**Mei Cong**, Promega Corporation, USA

08:25-08:50 **Title:** *Stability improvements to subunit and live attenuated influenza vaccines*

**Jessica A White**, PATH, USA

08:50-09:15 **Title:** *Heterotypic T cell responses to inactivated and live attenuated seasonal influenza vaccines*  
**Jay Bream**, Johns Hopkins Bloomberg School of Public Health, USA

09:15-09:40

**Title:** *Repeat annual seasonal influenza vaccination: The benefit of a changing vaccine formulation*  
**Ewan P. Plant**, Center for Biologics Evaluation and Research, US FDA

09:40-10:05 **Title:** *A split, inactivated influenza virus vaccine containing an engineered H5 hemagglutinin elicits broadly protective antibodies*  
**Maryann Giel-Moloney**, Sanofi Pasteur, USA

10:05-10:30 **Title:** *How close are we to realizing a hepatitis C vaccine- and do we need one?*  
**Andrea Cox**, Johns Hopkins University, USA

**Coffee Break & Networking 10:30-10:55**

### **New Vaccine Development**

**Session Chair:**

10:55-11:20 **Title:** *Systematic evaluation of self-assembling and self-adjuvanting lipopeptide vaccine candidates for the induction of protective immune responses*  
**Rachel Stephenson**, The University of Queensland, USA

11:20-11:45 **Title:** *Adjuvant-independent intranasal vaccination via human fcyRI-targeted fusion protein*  
**Edmund J. Gosselin**, Albany Medical College, USA

11:45-12:10 **Title:** *Antigen display and therapeutic potential of a buoyant VLP-like nanoparticle*  
**Shiladitya DasSarma**, University of Maryland School of Medicine, USA

12:10-12:35 **Title:** *Age to end dreadful diseases (HIV, Malaria, TB, cancer and more): A theory of Intact or Protected Complement (IPC) immunity*  
**Tom H. Jin**, IDT Biologika, USA

12:35-13:00 **Title:** *Regulation of Salmonella enterica serovar Typhi gene expression impacts intestinal epithelial cell responses and might affect the outcome of oral vaccines*  
**Rosangela Mezghanni**, University of Maryland School of Medicine, USA

**Lunch & Networking 13:00-14:00**

14:00-14:25 **Title:** *New approaches to prophylactic and therapeutic vaccines*  
**Scot Roberts**, Altimmune Inc. USA

14:25-14:50 **Title:** *Use of guinea pig anti-MVA antisera to theorize insights into MVA antigenicity in a vaccine platform*  
**Michael J Lacy**, Emergent BioSolutions, USA

14:50-15:15 **Title:** *Innovative mRNA vaccines – from proof of concept to product development*  
**Edith Jasny**, CureVac AG, Germany

15:15-15:40 **Title:** *Novel inactivated-alphavirus vaccine candidates*  
**Anuj Sharma**, Uniformed Services University of the Health Sciences, USA

**Coffee Break & Networking 15:40-16:00**

- 16:00-16:25 **Title:** *A new generation of versatile adjuvants*  
**Bror Morein**, Swedish University of Agriculture Sciences, Sweden
- 16:25-16:50 **Title:** *Fighting pathogens and toxins with human and human-like recombinant*  
**Esther Wenzel**, Technische Universität Braunschweig, Germany
- 16:50-17:15 **Title:** *A vaccine pipeline: phage display for identification of vaccine candidates, and for generation of human antibodies for diagnostics and therapy*  
**Gustavo Moreira**, Technische Universität Braunschweig, Germany
- 17:15-17:40 **Title:** *Characterization of significant molecular determinants of virulence of Enterovirus 71 sub-genotype B4 in Rhabdomyosarcoma cells*  
**Isabel Yee**, Sunway University, Malaysia

**Day-3 November 15, 2017**

**Track-E**

**DNA Vaccines**

**Vaccines Against Respiratory Pathogens**

**Session Chair:**

- 08:00-08:25 **Title:** *Cytolytic DNA vaccine to induce antigen cross-presentation by dendritic cells and liver tissue resident memory CD8+ T cells*  
**Danushka Kumara Wijesundara**, The University of Adelaide, Australia
- 08:25-08:50 **Title:** *APC-targeting of antigen for increased efficacy of DNA vaccination*  
**Gunnveig Grodeland**, University of Oslo, Norway
- 08:50-09:15 **Title:** *Approaches to improve HIV vaccine prospects*  
**Barbara K Felber**, National Cancer Institute, USA
- 09:15-09:40 **Title:** *Resident humoral response elicited by repeatedly same site inoculations inhibits systemic immunity of gene based vaccines*  
**Yanmin Wan**, University of Nebraska-Lincoln, USA
- 09:40-10:05  
**Title:** *Reshaping acellular pertussis vaccine-induced immune responses by the novel adjuvant, BcFA*  
**Purnima Dubey**, The Ohio State University, USA

**Coffee Break & Networking 10:05-10:30**

- 10:30-10:55 **Title:** *The Importance of RSV F protein conformation in stimulation of neutralizing antibodies in mice previously infected with RSV*  
**Trudy G Morrison**, University of Massachusetts Medical School, USA
- 10:55-11:20 **Title:** *Towards vaccines to prevent severe Respiratory Syncytial Virus in pediatric and older adult populations: combining the advantage of the Ad26 vector platform and a novel RSV prefusion F protein immunogen*  
**Benoit Callendret**, Janssen Vaccines & Prevention B.V., The Netherland

11:20-11:45 **Title:** *Pre-vaccination baseline levels of F-specific IgG and palivizumab epitope-specific antibodies predicted vaccine efficacy and failure*  
**Mark T. Esser**, MedImmune, USA

**Therapeutic Vaccination & Clinical Trials  
Technologies, Bioprocessing & Manufacturing**

**Session Chair: Ahmed Bouzidi**, Vaxéal Group, Switzerland

11:45-12:10 **Title:** *High therapeutic efficacy of a new cancer vaccine against the tumor associated antigen survivin*  
**Ahmed Bouzidi**, Vaxéal Group, Switzerland

12:10-12:35 **Title:** *The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus*  
**J. Patricia Dhar**, Wayne State University School of Medicine, USA

12:35-13:00 **Title:** *Systems and standard immunology demonstrated a prophylactic intradermal delivery of INO-4201 drives robust Ebola glycoprotein specific humoral and cellular immune responses in healthy volunteers in an open label phase I trial*  
**Jean Boyer**, Inovio Pharmaceuticals, USA

**Lunch & Networking 13:00-14:00**

14:00-14:25 **Title:** *The role of positive influence of Venom Immunotherapy (VIT) on other allergies*  
**Leonora Hana-Lleshi**, Allergologist-immunologist, Kosovo

14:25-14:50 **Title:** *Therapeutic vaccine against primate papillomavirus infections of the cervix*  
**Emeline Ragonnaud**, University of Copenhagen, Denmark

14:50-15:15 **Title:** *Pivotal role of cellular necrosis in residual cytotoxicity of a recombinant vaccine against Clostridium Difficile*  
**Laura Hong**, Vaccine Bioprocess & Bioanalytical Research, USA

15:15-15:40 **Title:** *Immunogenicity and therapeutic effects of recombinant Ag85AB fusion protein vaccines in mice infected with Mycobacterium tuberculosis*  
**Yan Liang**, the 309th Hospital of Chinese PLA

15:40-16:05 **Title:** *Formulation approaches to vaccine development*  
**S. Fernando Ausar**, Sanofi Pasteur, Canada

**Coffee Break & Networking 16:05-16:30**

16:30-16:55 **Title:** *BPZE1, a live attenuated pertussis vaccine: manufacturing challenges & solutions*  
**Marcel Thalen**, Iliad Biotechnologies, Belgium

16:55-17:20 **Title:** *Imaging of germinal center immune dynamics: Applications in vaccine development*  
**Constantinos Petrovas**, Vaccine Research Center, NIAID, NIH, USA

17:20-17:45 **Title:** *3M's hollow microneedle system and toll-like receptor 7/8 agonist 3M-052 for enhancing vaccine effectiveness*  
**Mark Tomai**, 3M Drug Delivery Systems, USA

**Speaker Slots Available**

**Reserve your slot**

[https://www.unitedscientificgroup.com/conferences/vaccines/registration\\_form](https://www.unitedscientificgroup.com/conferences/vaccines/registration_form)

**Submit your abstract**

[https://www.unitedscientificgroup.com/conferences/vaccines/abstract\\_submission](https://www.unitedscientificgroup.com/conferences/vaccines/abstract_submission)